Compare Western Alliance Bancorporation (WAL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Alliance Bancorporation vs State Street SPDR S&P Biotech ETF — how do they compare? Western Alliance Bancorporation trades at $74.46 (market cap $8.24B), while State Street SPDR S&P Biotech ETF trades at $153.76 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.23% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Western Alliance Bancorporation for 3 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| WAL | XBI | |
|---|---|---|
Market Cap | $8.24B | $10.11B |
Volume | 1,387,161 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $96.08 | $169.55 |
52-Week Low | $66.70 | $104.99 |
Typical Hold Time | 3 Days | 38 Days |
Enterprise Value | $9.76B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Alliance Bancorporation (WAL) trades at $74.41, showing minimal daily movement with a 0.08% gain. The stock presents compelling valuation metrics with a P/E of 8.52 and P/B of 1.09, while maintaining strong profitability with 25.43% net income margin. Recent Q2 2026 earnings matched expectations at $2.36 EPS, though technical indicators signal bearish momentum with resistance at $76-78 levels. The company continues to expand its digital banking platform with the recent WA VenueX launch.
WAL offers value investment potential with analyst consensus price target of $84.33 representing 13% upside. Strong institutional accumulation and 79% buy ratings support the bullish case, though bearish technical signals and potential regulatory changes for banks present near-term headwinds. The improving cash flow trend from -$500M to +$3.2B net cash flow in 2026 indicates strengthening financial position.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
